司美格鲁肽降糖药中国销售首次下滑
第一财经·2026-02-05 23:59
Core Viewpoint - Novo Nordisk's stock price fell by 8.14% on February 5 due to a decline in sales of its key diabetes drug, semaglutide, in the Chinese market for the first time [1] Sales Performance - Sales of the drug "Nuan Tai" in the Chinese market, including Hong Kong and Taiwan, decreased by 7% in 2025, amounting to approximately 5.4 billion Danish kroner (around 853 million USD) [1]